Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation

Jean El CheikhDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Correspondence[email protected]

Radwan MassoudDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon;

Basel HaffarDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon;

Elie FaresDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon;

Rami MahfouzDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon;

Tamima JisrDivision of Hematology and Oncology, Makassed University hospital, Beirut, Lebanon;

Mohamed A. Kharfan-DabajaDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, FL, USA

Anas MougharbelDivision of Hematology and Oncology, Makassed University hospital, Beirut, Lebanon;

Ali YoussefDivision of Hematology and Oncology, Makassed University hospital, Beirut, Lebanon;

Ali BazarbachiDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon;

Ahmad IbrahimDivision of Hematology and Oncology, Makassed University hospital, Beirut, Lebanon;

show all

Click to increase image sizeClick to decrease image size

Acknowledgments

We thank the nursing staff for providing excellent care for our patients and the physicians in the Hematology and Oncology division at the American University of Beirut Medical Center and Makassed University hospital and referring physicians from Lebanon and the Middle East region for their significant contributions and dedicated patients’ care.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at http://dx.doi.org/10.1080/10428194.2017.1307362.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation

Information for

Open access

Opportunities

Help and information

Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation

Acknowledgments

Potential conflict of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature